NCT00753467 - A Phase II Study to Determine the Safety and Efficacy of Interferon-gamma in Patients With Chronic Hepatitis B | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions

Hepatitis B

Interventions

DRUG

IFN-γ 1b (Actimmune)

IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose

DRUG

Adefovir dipivoxil

Adefovir dipivoxil: 1 tablet of 10mg given orally QD

DRUG

IFN-γ 1b and Adefovir dipivoxil combination

IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose Adefovir dipivoxil: 1 tablet of 10mg given orally QD

Trial Locations (1)

91105

Huntington Medical Research Institutes, Pasadena